Lumanity will be attending and presenting during the 2024 conference.
Panel Presentations:
Unlocking Longevity: Innovations, Investments, and the Future of Biotech
Dialogue 5B – October 29, 2024, 3:30pm
- Thomas Ichim, President & CSO, Immorta Bio
- Sergei Petukhov, Founder, Ludicrous Ventures
- Keara Sauber, Managing Director, Sauber Capital
- Robert Schneider, President & Co-Founder, Regerna Therapeutics
- Moderator: Ed Saltzman, Senior Strategic Advisor, Lumanity
The Future of Radiopharmaceuticals: Emerging Isotopes will Drive Breakthroughs in Oncology
Dialogue 8B – October 30, 2024, 3:00pm
In recent years, significant advancements have been made in the development of Pb-based alpha particle therapies, presenting promising new avenues for cancer treatment and enhanced diagnostic accuracy. Numerous studies have demonstrated the superior efficacy of these therapies against various cancer indications. However, questions remain regarding the long-term integration of lead in precision medicine. The panel will identify key isotopes, their potential applications, and the required quantities to meet anticipated healthcare needs.
- Ashley Mishoe, VP, Regulatory Affairs & Quality Assurance, PharmaLogic Holdings
- Bill Riddoch, VP, Product Development & Engineering, BWXT
- Thijs Spoor, CEO, Perspective Therapeutics
- Thom Tulip, CBO, Radiopharm Theranostics
- Moderator: Jeff Bockman, Expert Advisor and Executive Vice President, Oncology, Lumanity
Schedule time to meet with us by reaching out to contact@lumanity.com.